Portfolio

ImmTOR® and ImmTOR-IL™ have the potential to restore natural immune system balance by re-imagining immunotherapy for autoimmune disease, unlocking the potential of gene therapy and amplifying the efficacy of biologic therapy.
Find Out How

Pioneering Precision Immune Tolerance

Our ImmTOR® platform has the potential to overcome the challenges of autoimmunity and immunogenicity.

Image

Immunotherapies for Autoimmune Disease

Re-imagining Immunotherapy for Autoimmune Disease

The current standard of care for autoimmune disease is broad immunosuppression, which is associated with side effects and leaves patients vulnerable to serious infection and malignancies or symptom-masking treatments which do not address the underlying causes of the illness.

Our approach to autoimmune disease is highly differentiated and designed to restore natural immune system balance in vivo by co-administering IL-2 and ImmTOR® (ImmTOR-IL™) with nanoparticle-encapsulated self-antigens and avoid the need for chronic and systemic immune suppression.

Image

Gene TherapY

Unlocking the Potential of AAV Gene Therapy

ImmTOR® has the potential to induce adeno-associated virus (AAV) vector-specific immune tolerance, reducing the severity of the body’s immune response to AAV gene therapy and enabling repeat administrations.

Currently 30-70% of patients are ineligible for gene therapy due to natural pre-existing anti-AAV antibodies. Selecta’s novel, in-licesned IgG protease, Xork, has the potential to expand access to life-saving gene therapy for patients who would otherwise be unable to receive them.

Image

Biologic Therapy

Amplifying the Efficacy of Biologics

For many patients that require biologic therapy, the development of an immune response to the drug itself coincides with a loss of efficacy, often forcing them to discontinue treatment. When ImmTOR® is co-administered with immunogenic therapeutic biologics, it has the potential to ameliorate an immune response to the treatment, which would allow patients to continue to respond to treatment and stay on therapy longer.

Wholly-Owned Pipeline

Indication

          

Stage of Development

Preclinical
Phase 1
Phase 2
Phase 3

          

Commercial Rights

Re-imagining immunotherapy for autoimmune disease

Tolerogenic Therapies

Autoimmune liver diseases

0

0

21

0

0

Other autoimmune diseases

0

0

21

0

0

Amplifying the efficacy of biologic therapies

Biologic Therapies

IgA nephropathy (IgAN)

0

0

22

0

0

Partnered

Indication

Antigen

Stage of Development

Preclinical
Phase 1
Phase 2
Phase 3

          

Commercial Rights

Unlocking the potential of Gene Therapy

Gene Therapies

Pompe Disease

0

IgG Protease (Xork)

0

20

SEL-018

0

0

Duchenne muscular dystrophy (DMD)

0

Undisclosed

0

20

0

0

Limb-girdle muscular dystrophy (LGMD)

0

Undisclosed

0

20

0

0

Two indications for lysosomal storage disorder

0

Undisclosed

0

20

0

0

Amplifying the efficacy of biologic therapies

Biologic Therapies

Chronic Refractory Gout

0

Pegadricase

0

90

SEL-212

0

0

Image

Our Platform

ImmTOR® and ImmTOR-IL™: Precision Immune Tolerance Platform

ImmTOR® and ImmTOR-IL™ comprise an immune tolerance platform designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. This platform has the potential to restore natural immune system balance by re-imagining immunotherapy for autoimmune disease, unlocking the potential of gene therapy and amplifying the efficacy of biologic therapy.

Partner with us

Learn more about partnership opportunities

Selecta licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout, to Sobi in mid-2020. Selecta has also partnered with leading gene therapy companies, including Takeda, Sarepta Therapeutics and AskBio to evaluate the potential of ImmTOR® to enable redosing of life-saving gene therapy. Selecta is also looking for partnerships to unlock the potential of its proprietary IgG protease, Xork, for the mitigation of pre-existing anti-AAV antibodies.